Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Keratosis, Actinic 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Drugs, Generic × Clear all
NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Sanofi

Phase 2 Terminated
14 enrolled 15 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡